Tvardi Therapeutics, Inc.
TVRD
$7.00
$0.314.63%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
10/14/2025
-
MarketBeat
10/14/2025
-
Zacks Investment Research
10/14/2025
-
GuruFocus
10/14/2025
-
MarketBeat
10/14/2025
-
MarketBeat
10/14/2025
-
Simply Wall St
10/14/2025
-
MarketBeat
10/13/2025
-
Business Wire
10/13/2025
-
TipRanks Financial Blog
10/13/2025
-
TipRanks Financial Blog
10/13/2025
-
The Fly
10/13/2025
-
SeekingAlpha
10/13/2025
-
Benzinga
10/13/2025
-
Market News Video
10/13/2025
-
MarketBeat
10/13/2025
-
GuruFocus
10/13/2025
-
TipRanks Financial Blog
10/13/2025
-
The Fly
10/13/2025
-
MarketBeat
10/13/2025
-
MarketBeat
10/13/2025
-
TipRanks Financial Blog
10/13/2025
-
The Fly
10/13/2025
-
TipRanks Financial Blog
10/13/2025
-
The Fly
10/13/2025
-
GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Thursday, August 14, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of May 25 and 29 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
713 489 8654
Address
3 Sugar Creek Center Boulevard
Sugar Land, TX 77478
Sugar Land, TX 77478
Country
Year Founded
Business Description
Sector
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases...
more